Bristol-Myers Squibb Company (BMY) announced an update on their ongoing clinical study.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The LIBREXIA-STROKE study tests milvexian in people who recently had an ischemic stroke or high-risk mini-stroke. It aims to show that this pill can safely cut the risk of another stroke, which is a large unmet need and a key area of focus for Bristol-Myers Squibb and partners.
Milvexian is an oral drug that blocks a clotting factor in the blood. It is designed to lower the chance of new clots while trying to avoid the bleeding issues seen with some older blood thinners.
This is a phase 3 trial where people are randomly placed into two groups. One group gets milvexian and the other gets a placebo, with patients, doctors, and outcome teams all blinded so results stay unbiased.
The study first went to regulators in January 2023, marking the formal start of the program. The latest update was posted on February 12, 2026, which signals that recruitment is still active and the plan remains on track.
For investors, the update keeps the stroke franchise story alive for BMY and its partner Janssen’s parent, Johnson & Johnson. Positive phase 3 data could open a multi-billion dollar market and challenge current anticoagulant leaders, but delays or safety issues would weigh on sentiment.
The LIBREXIA-STROKE trial is active and progressing, and investors can find ongoing updates and protocol details on the ClinicalTrials.gov portal.
To learn more about BMY’s potential, visit the Bristol-Myers Squibb Company drug pipeline page.